Cofactor Genomics has announced promising results for its OncoPrism test, demonstrating enhanced specificity in predicting patient response to immunotherapy. The announcement follows recent milestones, including Medicare coverage for OncoPrism in head and neck cancer patients and clinical validation in non-small cell lung cancer (NSCLC). These advancements underscore the potential of RNA-based diagnostics in improving treatment guidance for cancer patients.
The company's national clinical trial (PREDAPT) has shown that OncoPrism offers a threefold increase in specificity over PD-L1 and a fourfold increase in specificity over TMB, the two most widely used clinical tests for guiding immunotherapy decisions. Specificity, in this context, refers to the test's ability to correctly identify patients who will not benefit from immunotherapy, thus avoiding unnecessary treatment and associated side effects.
Expanding Clinical Evidence
Cofactor Genomics is actively expanding the clinical evidence for OncoPrism through the PREDAPT multi-site clinical trial (NCT04510129). This trial is evaluating the test's performance across 11 solid tumor cancers, including those beyond head and neck cancer and NSCLC. This aggressive clinical evidence expansion aims to solidify OncoPrism's utility in a broader range of cancer types.
RNA-Based Precision Medicine
Cofactor Genomics utilizes its proprietary PRISM database of patented Health Expression Models (HEMs) to decode RNA and address critical challenges in healthcare. HEMs represent a significant advancement over traditional gene mutation panel tests, leveraging machine learning and RNA analysis to transform vast amounts of biological data into high-dimensional models of biology, disease, and therapy response.
Cofactor's approach has garnered recognition in publications such as The Journal of ImmunoTherapy of Cancer and The Journal of Molecular Diagnostics. The company is supported by 38 healthcare systems, representing 20% of US healthcare, and OncoPrism is CAP/CLIA-validated and Medicare-approved, highlighting its clinical validity and utility.
